BeOne Medicines (ONC) said Wednesday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a new film-coated tablet formulation of its Brukinsa B-cell cancer drug for all approved indications.
The opinion is subject to a review by the European Commission, which will grant the marketing authorization for the tablet formulation in the region.
The company said it will start converting Brukinsa to tablets from capsules in regions outside China in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.